EUVIMEDΑνακαλύψτε το EUVIMED
Crossref

Experimental high blood glucose metabolically rejuvenates CD8+ T cells for improved control of tumor growth through an IGF1-IGF1R axis

Anirban Sarkar, Sukanya Dhar, Saurav Bera, Mohona Chakravarti, Ayushi Verma, Muqtada Ali Khan, Parash Prasad, Anupam Das, Pritha Roy Choudhury, Jasmine Sultana, Juhina Das, Akata Saha and 11 more

The Journal of Immunology · 2026-10-01 · 215 (10)

DOI: 10.1093/jimmun/vkag262 ↗

At a glance

Journal article in The Journal of Immunology, published online on 2026-10-29. Written by Anirban Sarkar and 22 co-authors. Institution: Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India. Major MEDLINE topics: CD8-Positive T-Lymphocytes, Insulin-Like Growth Factor I, Receptor, IGF Type 1, Blood Glucose. 51 references. Funded by: University Grant Commission, New Delhi, Government of India, Indian Council of Medical Research, New Delhi, India, 45/04/2022-IMM/BMS.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Epidemiologic studies suggest that patients with pre-existing type 1 diabetes have a decreased risk of developing melanoma, prostate cancer, and breast cancer, although the underlying mechanism remains unresolved. In translational model studies, we observed that a streptozotocin-induced high blood glucose model exhibited restricted melanoma and carcinoma (mammary, lung, and colon) growth in association with extended overall survival. Tumor-infiltrating CD8+ T cells were responsible for tumor growth restriction. Tumor-infiltrating CD8+ T cells but not tumor cells themselves exhibited higher glycolytic and cytotoxic activity in high-glucose hosts. Such improved antitumor T cell function was linked to upregulated expression of Igf1, Igf1R, and phospho-mTOR in CD8+ T cells in the tumor microenvironment. High blood glucose patient-derived peripheral CD8+ T cells displayed superior activation in vitro after allogenic tumor antigen stimulation versus nondiabetic CD8+ T cells. Activation of high-glucose-patient CD8+ T cells was sensitive to targeted antagonism of IGF1R and mTOR, supporting the operational involvement of the IGF1R-mTOR signaling axis. Our results suggest that selective activation of the intrinsic IGF1R-mTOR signaling axis in CD8+ T cells serves as a preferred endpoint to achieving more effective immunotherapy outcomes in cancer patients.

Subjects

MeSH terms (MEDLINE)

CD8-Positive T-LymphocytesInsulin-Like Growth Factor IReceptor, IGF Type 1Blood GlucoseDiabetes Mellitus, ExperimentalAnimalsMiceSignal TransductionHumansTOR Serine-Threonine KinasesTumor MicroenvironmentMaleLymphocytes, Tumor-InfiltratingCell Line, TumorFemaleMice, Inbred C57BL

Author keywords

CD8 T cellshigh glucose modelinsulin like growth factor 1insulin like growth factor 1 receptortumor microenvironment

Substances

Insulin-Like Growth Factor IReceptor, IGF Type 1TOR Serine-Threonine KinasesBlood GlucoseIgf1r protein, mouse

Authors and institutions

  • Department of Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, India.
  • Cancer Biology Division, CSIR-Central Drug Research Institute, Lucknow, India.
  • Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
  • Department of Pharmaceutical Technology (Biotechnology), National Institute of Pharmaceutical Education and Research, Mohali, India.
  • Department of Clinical Biochemistry, Doyen Diagnostics & Research Foundation, Kolkata, India.
  • Department of Endocrinology, R. G. Kar Medical College and Hospital, Kolkata, India.

Funding

  • University Grant Commission, New Delhi, Government of India
  • Indian Council of Medical Research, New Delhi, India
  • 45/04/2022-IMM/BMS

Cite

APA

Sarkar, A., Dhar, S., Bera, S., Chakravarti, M., Verma, A., Khan, M. A., Prasad, P., Das, A., Choudhury, P. R., Sultana, J., Das, J., Saha, A., Bhuniya, A., Guha, I., Dasgupta, S., Roy, S. S., Banerjee, S., Roy, S., Bhar, D., …, & Bose, A. (2026). Experimental high blood glucose metabolically rejuvenates CD8+ T cells for improved control of tumor growth through an IGF1-IGF1R axis. The Journal of Immunology, 215(10). https://doi.org/10.1093/jimmun/vkag262

Vancouver

Sarkar A, Dhar S, Bera S, Chakravarti M, Verma A, Khan MA, et al. Experimental high blood glucose metabolically rejuvenates CD8+ T cells for improved control of tumor growth through an IGF1-IGF1R axis. The Journal of Immunology. 2026;215(10). doi:10.1093/jimmun/vkag262

BibTeX
@article{Sarkar2026,
  author = {Sarkar, Anirban and Dhar, Sukanya and Bera, Saurav and Chakravarti, Mohona and Verma, Ayushi and Khan, Muqtada Ali and Prasad, Parash and Das, Anupam and Choudhury, Pritha Roy and Sultana, Jasmine and Das, Juhina and Saha, Akata and Bhuniya, Avishek and Guha, Ipsita and Dasgupta, Shayani and Roy, Sib Sankar and Banerjee, Saptak and Roy, Subir and Bhar, Debarati and Storkus, Walter J and Baral, Rathindranath and Datta, Dipak and Bose, Anamika},
  title = {Experimental high blood glucose metabolically rejuvenates CD8+ T cells for improved control of tumor growth through an IGF1-IGF1R axis},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {10},
  doi = {10.1093/jimmun/vkag262}
}
Start for free →